Boehringer Ingelheim (Schweiz) GmbH
Boehringer Ingelheim (Schweiz) GmbH is a Originators company based in Basel (Basel-Stadt) recorded by Swissmedic as the authorisation holder for 28 human medicines. That places it 64 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Synthetika.
Key facts
| Sector | Originators |
|---|---|
| City | Basel |
| Canton | Basel-Stadt |
| Authorisation holder | Yes |
| Medicines | 28 |
| Founded | Not available |
| Employees | 201-1000 |
| Parent group | Boehringer Ingelheim |
| Activity | Not available |
| Website | boehringer-ingelheim.com/ch |
Medicines authorised in Switzerland
Boehringer Ingelheim (Schweiz) GmbH is recorded by Swissmedic as the authorisation holder for 28 human medicines. The table shows 28 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
28 of 28 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Actilyse 20mg | 48313 | B | B01AD02 | 1988-09-19 |
| Actilyse Cathflo 2mg | 58665 | B | B01AD02 | 2009-07-10 |
| Atrovent 250 mcg/2 ml | 52584 | B | R03BB01 | 1994-11-15 |
| Berodual N | 55501 | B | R03AL01 | 2001-09-03 |
| Dospir | 53844 | B | R03AL02 | 1997-11-24 |
| Giotrif 20 mg | 63042 | A | L01EB03 | 2014-01-17 |
| Glyxambi 10 mg / 5 mg | 66132 | B | A10BD19 | 2017-03-29 |
| Jardiance 25 mg | 63227 | B | A10BK03 | 2014-11-12 |
| Jardiance Met 5 mg/500 mg | 65570 | B | A10BD20 | 2015-11-12 |
| Jentadueto 2.5 mg/500 mg | 62492 | B | A10BD11 | 2012-10-04 |
| Metalyse 10'000 U | 55418 | B | B01AD11 | 2000-06-29 |
| Metalyse 5'000 U | 69958 | B | B01AD11 | 2025-08-18 |
| Micardis 40 mg | 54780 | B | C09CA07 | 1998-12-16 |
| Micardis Amlo 40/5 mg | 61270 | B | C09DB04 | 2010-11-08 |
| Micardis Plus 80/12 | 55970 | B | C09DA07 | 2002-08-30 |
| OFEV 100 mg | 65330 | B | L01EX09 | 2015-08-13 |
| Pradaxa 75 mg | 61385 | B | B01AE07 | 2012-05-29 |
| Pradif T | 57160 | B | G04CA02 | 2005-06-24 |
| Praxbind 2.5 g | 65804 | A | V03AB37 | 2016-07-20 |
| Sifrol 0 | 54277 | B | N04BC05 | 1997-12-10 |
| Sifrol ER 0 | 60057 | B | N04BC05 | 2010-06-10 |
| Spiolto Respimat 2.5 mcg / 2.5 mcg | 67352 | B | R03AL06 | 2019-04-11 |
| Spiriva 18 mcg | 55855 | B | R03BB04 | 2002-12-16 |
| Spiriva Respimat 2.5 mcg | 67396 | B | R03BB04 | 2019-05-02 |
| Striverdi Respimat 2.5 mcg | 67399 | B | R03AC19 | 2019-05-02 |
| Trajenta | 61893 | B | A10BH05 | 2012-03-08 |
| Viramune | 54393 | A | J05AG01 | 1997-12-23 |
| Viramune | 62077 | A | J05AG01 | 2012-01-10 |
Frequently asked questions
How many medicines does Boehringer Ingelheim (Schweiz) GmbH have authorised in Switzerland?
Boehringer Ingelheim (Schweiz) GmbH is recorded by Swissmedic as the authorisation holder for 28 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Boehringer Ingelheim (Schweiz) GmbH based?
The Swiss location recorded for Boehringer Ingelheim (Schweiz) GmbH is Basel, Basel-Stadt.
Is Boehringer Ingelheim (Schweiz) GmbH a Swissmedic authorisation holder?
Yes. Boehringer Ingelheim (Schweiz) GmbH appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.